Breaking News

INC Research Names General Medicine EVP

July 3, 2013

Braithwaite brings 25 years of experience

Ian M. Braithwaite, Ph.D., has been appointed executive vice president and general manager of General Medicine at INC Research. Dr. Braithwaite will provide global leadership for the company’s General Medicine business unit, which specializes in conducting trials in areas ranging from infectious disease, respiratory disease, women’s health, immunology and inflammation, gastrointestinal disease and ophthalmology. Dr. Braithwaite will be based out of INC’s Camberley, UK, office.
 
Dr. Braithwaite brings 25 years of experience in the CRO and biopharmaceutical industries with particular expertise in immuno-inflammatory diseases. He joins the company from PPD, where he served as global therapeutic area head, General Medicine. Under his leadership, this unit experienced significant growth in revenue and backlog, boosted staff utilization and reduced turnover. Dr. Braithwaite previously served in other senior positions at PPD, including executive director and therapeutic head for Europe, Middle East and Africa, and executive director, project management performance.
 
“We are excited to add an experienced leader like Dr. Braithwaite to our therapeutic leadership team,” said Jamie Macdonald, INC’s chief executive officer. “Ian’s deep therapeutic experience both in the CRO and biopharmaceutical space provides a unique perspective on the efficient management of clinical development programs. As a CRO structured around a strong therapeutic focus, world-class leadership in our business units is critical to our success. Ian is responsible for significantly growing our presence in this important fast-growing market segment.”

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important